Premium
Icodextrin reduces the risk of congestive heart failure in peritoneal dialysis patients
Author(s) -
Wang IKuan,
Lin ChengLi,
Yen TzungHai,
Lin ShihYi,
YaoLung Liu,
Sung FungChang
Publication year - 2018
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.4412
Subject(s) - icodextrin , medicine , peritoneal dialysis , heart failure , diabetes mellitus , incidence (geometry) , hazard ratio , cardiology , dialysis , endocrinology , confidence interval , physics , optics
Purpose Icodextrin can enhance ultrafiltration and consequently improve fluid balance and can control blood pressure and reduce left ventricular mass for peritoneal dialysis (PD) patients. This study investigated whether icodextrin use could reduce the risk of congestive heart failure (CHF) for PD patients. Methods From the Taiwan National Health Insurance database, we identified 5462 newly diagnosed end‐stage renal disease patients undergoing PD from 2005 to 2010. Incidence rates and hazard ratio of CHF were estimated for patients with and without icodextrin treatment by the end of 2011. Results Among PD patients, icodextrin users had an overall 26% lower incidence of CHF than non‐users (13.7 vs 18.6 per 1000 person‐years). Relatively, the adjusted hazard ratio was 0.67 (95% CI = 0.52–0.87) for users compared with non‐users. Among PD patients with diabetes, the incident CHF in icodextrin users was 37.5% lower than that in non‐users (17.8 vs 28.5 per 1000 person‐years). Among PD patients without diabetes, the incident CHF in icodextrin users was 30.4% lower than that in non‐users (11.0 vs 15.8 per 1000 person‐years). Conclusions Icodextrin solution could reduce the risk of new‐onset CHF, particularly effective when diabetic PD patients use it.